#United States #CML #Boulder #Enliven Therapeutics #ELVN-001

Enliven Therapeutics Reports Third Quarter Results

Enliven Therapeutics, Inc. (Nasdaq: ELVN), a biopharmaceutical company specializing in developmental therapies, has made notable strides in its operations. The company announced its financial results for the third quarter of 2025, revealing a robust business position with a strong focus on advancing its clinical trials.

Financial Overview

As of September 30, 2025, Enliven's cash reserves stand at an impressive $477.6 million. This capital is forecasted to sustain the company through to the first half of 2029, which presents a solid foundation for continued research and development. In the third quarter, research and development expenses decreased to $18.2 million, down from $21.3 million in the prior year, while administrative costs rose to $6.9 million from $5.8 million. As a result, Enliven reported a net loss of $20.1 million for the quarter, an improvement from the $23.2 million loss recorded in Q3 of 2024.

Progress in Clinical Trials

CEO Sam Kintz expressed his satisfaction with the progress of the ENABLE Phase 1 clinical trial of ELVN-001, a treatment aimed at chronic myeloid leukemia (CML) patients. The company completed its Phase 1b portion during this quarter, setting the stage for a planned global Phase 3 trial in 2026. The ENABLE trial assesses the efficacy of ELVN-001, a selective kinase inhibitor targeting the critical BCR-ABL fusion gene responsible for CML.

In addition, Enliven is actively participating in the medical community, recently presenting findings from the ENABLE trial at several prestigious conferences. This includes the Society of Hematologic Oncology (SOHO) Annual Meeting in September, European Society of Hematology's chronic myeloid leukemia conference in October, and the German, Austrian, and Swiss Hematology and Oncology societies' meeting later in October.

Upcoming Events and Future Plans

Looking ahead, Enliven has announced plans for additional presentations at significant medical gatherings, including the 67th Annual American Society of Hematology (ASH) meeting in December 2025 where they will present data from their ENABLE trial. Furthermore, management will engage with investors during a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2025, which will be accessible online for those unable to attend.

The ENABLE trial is designed to thoroughly evaluate the safety and effectiveness of ELVN-001 in patients with relapsed or refractory cases. It also encompasses secondary endpoints that include pharmacokinetics and the correlation between the treatment and the reduction of BCR-ABL transcript levels.

About Enliven Therapeutics

Founded in Boulder, Colorado, Enliven Therapeutics is committed to improving the lives of patients through innovative therapies targeting unsolved medical needs. The company’s strategy derives from deep biological insights that guide their drug discovery process, aiming to establish effective treatments for various cancers, particularly within the realm of precision oncology.

In summary, with a healthy financial status and significant clinical developments underway, Enliven Therapeutics is poised for a promising future in the biopharmaceutical industry. Investors and the medical community alike are encouraged to follow the forthcoming advancements of ELVN-001 as it progresses towards pivotal trials.